117 related articles for article (PubMed ID: 19224452)
1. Biomarkers for novel targeted therapies of hepatocellular carcinoma.
Okamoto K; Neureiter D; Ocker M
Histol Histopathol; 2009 Apr; 24(4):493-502. PubMed ID: 19224452
[TBL] [Abstract][Full Text] [Related]
2. [Targeted therapies in hepatocellular carcinomas: recent results and future development].
Marijon H; Faivre S; Raymond E
Bull Cancer; 2009 May; 96(5):553-61. PubMed ID: 19467986
[TBL] [Abstract][Full Text] [Related]
3. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of hepatocellular carcinoma: present and future.
Chan SL; Yeo W
J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
7. [Hepatocellular carcinoma: novel therapeutic approaches].
Mohr L
Praxis (Bern 1994); 2007 Apr; 96(14):553-62. PubMed ID: 17455567
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting for treatment of advanced hepatocellular carcinoma.
Song IH
Korean J Hepatol; 2009 Sep; 15(3):299-308. PubMed ID: 19783879
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
11. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
Kaseb AO; Hanbali A; Cotant M; Hassan MM; Wollner I; Philip PA
Cancer; 2009 Nov; 115(21):4895-906. PubMed ID: 19637355
[TBL] [Abstract][Full Text] [Related]
13. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice.
Okamoto K; Neureiter D; Alinger B; Meissnitzer M; Sass G; Schmitz V; Di Fazio P; Wissniowski T; Gahr S; Hohenstein B; Kaufmann B; Schlösser A; Haus U; Hahn EG; Herold C; Ocker M
Int J Oncol; 2008 Oct; 33(4):733-42. PubMed ID: 18813786
[TBL] [Abstract][Full Text] [Related]
14. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
15. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
16. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
17. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Zhu AX
Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
[TBL] [Abstract][Full Text] [Related]
18. Role of novel targeted therapies in the clinic.
Herbst RS
Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S21-7. PubMed ID: 15928655
[TBL] [Abstract][Full Text] [Related]
19. TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma?
De Palma M; Coukos G; Semela D
Hepatology; 2013 Apr; 57(4):1294-6. PubMed ID: 22911438
[No Abstract] [Full Text] [Related]
20. Vascular endothelial growth factor and its type 2 receptor in hepatocellular carcinoma.
Gershtein ES; Dubova EA; Shchegolev AI; Kushlinskii NE
Bull Exp Biol Med; 2010 Nov; 149(6):749-52. PubMed ID: 21165437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]